Doxorubicin Hydrochloride is named as a drug or biological intervention in 5 clinical trials in our China and USA trial registers, 2 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (2), Genmab (1) and BeBetter Med Inc (1). Registered phases: Phase 2 and Phase 2/3. Conditions studied include Follicular Lymphoma; Breast Neoplasms; Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Follicular Lymphoma | 1 |
| Breast Neoplasms | 1 |
| Breast Cancer | 1 |
| Non-Hodgkin Lymphoma | 1 |
| Previously Untreated Peripheral T-Cell Lymphoma | 1 |
| Soft Tissue Sarcoma | 1 |
| Melanoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 2 |
| Genmab | 1 |
| BeBetter Med Inc | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Register | Doxorubicin Hydrochloride trials |
|---|---|
| Clinical trials in China | 4 |
| Clinical trials in USA | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Doxorubicin Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Doxorubicin Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.